RECEIVE

Approved for use through ag

	· •	•		•
•	•		1	,
				/
Plans	ca hm	a a okia ele	on (4) in aid	e this box ->
	~ GP	o a hinz zil)11 (+) #15K	e uns box —>

e Paperwork Reduction Act of 1995, no persons are required to respond to a	Patent and Trademark Ottice	US MED 1317 XYE (10MB 0651-
Paperwork Reduction Act of 1995, no persons are required to respond to a	collection of information unless	H DE TELEFORME COMME
		nu loranco BMO ontrol nu
		The same of the sa

CONTINUED PROSECUTION APPLICATION (CPA) REQUEST TRANSMITTAL

Submit an original, and a duplicate for fee processing. (Only for Continuation or Divisional applications under 37 CFR 1.53(d)) CHECK BOX, if applicable: DUPLICATE

Address to:

Assistant Commissioner for Patents **Box CPA** Washington, DC 20231

		_
Attorney Docket No.	146.1275	
First Named Inventor	MAKISHINA et al	_
Express Mail Label No.	EL 783039765 US	_
Total Pages	4	

		divisional application under 37 CFR 1.53(d).
	pplication (CPA)) of pric	r application number 08 / 945,459
filed on 10/20/97	, entitled_A_NOVEL_1	PROTEIN AND PROCESS FOR PREPARING THE SAME

NOTES

FILING QUALIFICATIONS: The prior application identified above must be a nonprovisional application that is either (1) complete as defined by 37 CFR 1.51(b) and filed on or after June 8, 1995, or (2) the national stage of an international application in compliance with 35 U.S.C. 371 and filed on or after June 8, 1995.

C-I-P NOT PERMITTED: A continuation-in-part application cannot be filed as a CPA under 37 CFR 1.53(d), but must be filed under 37 CFR 1.53(b).

EXPRESS ABANDONMENT OF PRIOR APPLICATION: The filing of this CPA is a request to expressly abandon the prior application as of the filing date of the request for a CPA. 37 CFR 1.53(b) must be used to file a continuation, divisional, or continuation-in-part of an application that is not to be abandoned.

ACCESS TO PRIOR APPLICATION: The filing of this CPA will be construed to include a waiver of confidentiality by the applicant under 35 U.S.C. 122 to the extent that any member of the public who is entitled under the provisions of 37 CFR 1.14 to access to copies of, or information concerning, the prior application may be given similar access to, copies of or similar information concerning, the other application or applications in the file jacket.

35 U.S.C. 120 STATEMENT: In a CPA; no reference to the prior application is needed in the first sentence of the specification and none should be submitted. If a sentence referencing the prior application is submitted, it will not be entered. A request for a CPA is the specific reference required by 35 U.S.C. 120 and to every application assigned the application number identified in such request, 37 CFR 1.78(a).

1. []	Enter the unentered amendment previously filed on under 37 CFR 1.116 in the prior nonprovisional application. A preliminary amendment is enclosed.
	s application is filed by fewer than all the inventors named in the prior application, 37 CFR 1.53 (d)(4).
b. 4.	•••••••••••••••••••••••••••••••••••••••

[Page 1 of 2]

Patents, Box CPA, Washington, DC 20231.

RECEIVED

Approved for use through 0.950.00. OMB 0651-0032

Approved for use through 0.950.00. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Patent And Trademark OFFICE: U.S

PATENY	LAIMS		·	r	TEN	LA-
PALE	**************************************	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CAEEU 160/2/26
		TOTAL CLAIMS (37 CFR 1.18(c))	32 -20 =	12	×\$ <u>18</u> =	\$ 216.00
		INDEPENDENT CLAIMS(37 CFR 1.16(b))	1 -3=	0	x \$=	0
		MULTIPLE DEPENDE	NT CLAIMS (if applicabl	e) (37 CFR 1.16(ග))	+ \$=	0
					BASIC FEE (37 CFR 1.18(a))	
				Total of abo	ve Calculations =	710.00
		Reduction by 50	% for filing by small ent	ity (Note 37 CFR 1.9, 1.27,	1.28).	\$926.00
					TOTAL =	\$926.00
6. Sr		y status:				122000
a.	☐ As	mall entity statemen	nt is enclosed.			
b.	\square A sign and	mall entity statemer such status is still	nt was filed in the proper and desired	rior nonprovisional ap	plication	
,	<u> </u>	o longer claimed.				
7. Th	e Comm	nissioner is hereby a	authorized to credit	overpayments or cha	rao the fell-	
				*	ige the following	g tees to
	a. Fees required under 37 CFR 1.16.					
0.[b. Fees required under 37 CFR 1.17.					
0 [required under 37				
		in the amount of \$		is enclosed.	_	
3. LXI	Other: .	PIO FORM 20	38 enclosed	authorizing	fees.	

NOTE.		The prior applica UNLESS a new co	tion's correspond orrespondence ad	ence address will ca dress is provided be	arry over to this	s CPA
		, 10. N	IEW CORRESPOND	FNCE ADDRESS		
Custom	ner Number	or Bar Code Label		i i		
	20311 (Insert Custofferting Agreement Code label here)				lence address below	
IAME	Ch	arles A. Mus	erlian			
	Bierman, Muserlian and Lucas					

11. 5	SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED
NAME	
SIGNATURE	Charles A. Muserlian
DATE	April 18, 2001
	2001

N.Y.

212 661-8000

ZIP CODE

10016

212 661-8002

STATE

TELEPHONE

ADDRESS

COUNTRY

CITY

600 Third Avenue

New York

U.S.A.



"EXPRESS MAIL" Mailing Label Number <u>EL 783039765 US</u>

Date of Deposit: April 18, 2001

I hereby certify that this correspondence is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" Service under 37 C.R.F. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Charles A. Muserlian, Reg. No. 19,683

Date: April 18, 2001



146.1275

24 PP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

D. Romeo

F. MAKISHMINA et al

Serial No.: 945,459

Group: 1646

Filed: October 20, 1997

:

For: NOVEL PROTEIN...THE SAME

600 Third Avenue New York, N.Y. 10016

April 18, 2001

AMENDMENT

Asst.Commissioner for Patents Washington, D.C. 20231

Sir:

Please amend this application as follows:

IN THE CLAIMS:

Cancel all the claims and add the following claims:

--17. An isolated protein consisting of the 119 amino acids as shown in SEQ ID No: 1 without residual proteins consisting of the amino acid sequence as shown in SEQ ID No: 1, the said protein with an additional Ala (120 amino acids) and the said protein with Met and Ala (121 amino acids) at the N-terminus.

- 18. An isolated protein according to claim 17 wherein said protein is a homodimer.
- 19. A pharmaceutical composition comprising the protein of claim 18 and a pharmaceutical carrier.

20. The pharmaceutical composition of claim 19 comprising an amount of the protein of claim 18 effective to treat cartilage and/or bone diseases.